TABLE 2.
StudyTime post-transplantInteracting drugs | Statistical analysis | Covariates tested | Significant predictors/correlations |
---|---|---|---|
A. Kidney Transplants | |||
Capron et al. (2010) | Multiple linear regression | Recipient Genetics: | Day 7 C0PBMC/C0Blood: |
Day 7 and steady-state (1 month)Not excluded | ABCB1 1199G>A, 2677G>T/A, 3435C>TCYP3A5*3Other: age, plasma bilirubin, plasma creatinine, total PPr, MCV | 1199GA β = 0.3148 p = 0.00033435CT β = 0.1152 p = 0.02383435TT β = 0.1727 p = 0.0033PPr β = −1.2364 p = 0.0051Steady-state C0PBMC/C0Blood:1199GA β = 0.4123 p = 0.0,0883435CT β = 0.1435 p = 0.0125PPr β = −0.9867 p = 0.0328 | |
Han et al. (2016)Steady-state (up to 14 years post-transplant)Excluded | ANCOVA | Recipient Genetics:ABCB1 1236C>T, 2677G>T/A, 3435C>TOther: age; sex; donor type; previous transplantation; diabetes mellitus; delayed graft function; acute rejection; recurrent original disease; CNI-nephrotoxicity; duration of transplantation | Steady-state C0PBMC/C0Blood: sex F = 5.111 p = 0.025haematocrit F = 4.579 p = 0.034transplant duration F = 7.233 p = 0.008 |
Francke et al. (2020)Steady-state (3 months)Excluded (up to 3 months post-transplant) | Multiple linear regression | Recipient Genetics:ABCB1 1199G>A, 3435C>TCYP3A4*22, CYP3A5*3Other: age, gender, haematocrit, serum albumin, serum creatinine | Steady-state C0PBMC/C0Blood:age β = 0.0229, p = 0.048albumin β = 0.1275, p = 0.007haematocrit β = −16.138, p < 0.001 |
B. Liver Transplants | |||
Tron et al. (2020)Approximately 1 weekExcluded | 1Mann-Whitney or Kruskal-Wallis tests, with Bonferroni correction, as appropriate2Univariate correlation analyses | 1Donor & Recipient Genetics:ABCB1 1199G>A, 1236C>T, 2677G>T/A, 3435C>TCYP3A4*22; CYP3A5*3 2Other: age, sex, body weight, albumin, haematocrit, PBMC cell number | 1Week one AUCPBMC/AUCBlood: recipient ABCB1 2677TT (p < 0.05)recipient ABCB1 1236/2677/3435 homozygous TTT (p < 0.05)2Week one AUCPBMC/AUCBlood: haematocrit r = -0.34, p = 0.036 |
MCV = mean corpuscular volume, PPr = plasma protein. Statistical analysis performed for 1pharmacogenetic or 2other comparisons in (Tron et al., 2020).